Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

Personalized Education (powered by ACHL AdaptED®)

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized education is essential to accommodate early career providers, community oncologists, and advanced specialists. The ACHL AdaptEd® platform achieves this by expanding and contracting to accommodate different learning needs to achieve meaningful results. 

Faculty: Faiz Anwer, MD, FACP, Surbhi Sidana, MD

Release Date: December 22, 2023

Expiration Date: December 22, 2024

CME/CE is no longer available for this activity